INMED Competitors

MWG0 Stock

4.14 0.75 15.34%

INMED PHARMACEUTICALS INC competes with Apple, Apple, Apple, Apple, and Apple; as well as few others. Analyzing INMED PHARMACEUTICALS competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of INMED PHARMACEUTICALS to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out INMED PHARMACEUTICALS Correlation with its peers.

For more detail on how to invest in INMED Stock please use our How to Invest in INMED PHARMACEUTICALS guide.

You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of INMED PHARMACEUTICALS competition on your existing holdings.

Specify up to 10 symbols:

Hype

Prediction

Low	Estimated	High
0.21	4.14	14.15

Details

Intrinsic

Valuation

Low	Real	High
0.19	3.71	13.72

Details

INMED PHARMACEUTICALS Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between INMED PHARMACEUTICALS and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of INMED and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of INMED PHARMACEUTICALS INC does not affect the price movement of the other competitor.

	APC	APC	APC	APC	APC	APC	MSF	MSF	MSF	MSF
APC		1.0	1.0	1.0	0.99	1.0	0.94	0.93	0.93	0.92	APC
APC	1.0		1.0	1.0	0.99	1.0	0.94	0.93	0.93	0.92	APC
APC	1.0	1.0		1.0	0.99	0.99	0.93	0.92	0.93	0.92	APC
APC	1.0	1.0	1.0		0.99	1.0	0.93	0.92	0.92	0.92	APC
APC	0.99	0.99	0.99	0.99		0.99	0.93	0.93	0.93	0.92	APC
APC	1.0	1.0	0.99	1.0	0.99		0.93	0.92	0.92	0.92	APC
MSF	0.94	0.94	0.93	0.93	0.93	0.93		0.99	1.0	0.99	MSF
MSF	0.93	0.93	0.92	0.92	0.93	0.92	0.99		0.99	0.99	MSF
MSF	0.93	0.93	0.93	0.92	0.93	0.92	1.0	0.99		0.99	MSF
MSF	0.92	0.92	0.92	0.92	0.92	0.92	0.99	0.99	0.99		MSF
	APC	APC	APC	APC	APC	APC	MSF	MSF	MSF	MSF

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

Please upgrade your account to get full access to Macroaxis premium features

Risk-Adjusted Indicators

There is a big difference between INMED Stock performing well and INMED PHARMACEUTICALS Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze INMED PHARMACEUTICALS's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
APC	0.88	0.27	0.21	1.34	0.89	(0.99)	1.81	(1.75)	4.97
APC	0.85	0.26	0.19	0.94	0.98	(0.93)	1.88	(1.73)	5.24
APC	0.86	0.26	0.22	0.75	0.84	(0.95)	2.06	(1.76)	4.50
APC	0.93	0.27	0.18	15.95	1.04	(0.99)	2.22	(1.83)	6.45
APC	0.95	0.28	0.24	5.15	0.74	(1.11)	2.83	(1.69)	5.24
APC	0.84	0.27	0.21	1.52	1.00	(0.95)	1.88	(1.61)	6.46
MSF	0.96	0.11	0.07	0.57	1.25	(1.17)	2.55	(1.46)	8.71
MSF	1.05	0.11	0.06	1.51	1.38	(1.17)	2.35	(1.75)	9.11
MSF	1.00	0.11	0.06	1.06	1.48	(1.16)	2.42	(1.66)	11.42
MSF	0.92	0.11	0.06	(14.37)	1.33	(1.00)	2.04	(1.49)	8.79

Unable to evaluate fundamental data of [APC.DU, APC.HM, APC.HA, APC.MU, APC.BE, APC.STU, MSF.DU, MSF.MU, MSF.HM, MSF.BE] at this time. Please try again later

All Fundamental Data

INMED PHARMACEUTICALS Competitive Analysis

The better you understand INMED PHARMACEUTICALS competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, INMED PHARMACEUTICALS's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across INMED PHARMACEUTICALS's competition over several years is one of the best ways to analyze its investment potential.

Better Than Average

Worse Than Peers

View Performance Chart

	MWG0	APC	APC	APC	APC	APC	APC	MSF	MSF	MSF
	15.34 4.14 INMED	0.68 243.85 Apple	0.51 244.55 Apple	1.41 244.90 Apple	1.60 245.00 Apple	3.16 245.10 Apple	0.62 245.00 Apple	0.71 418.30 Microsoft	0.85 419.65 Microsoft	0.57 419.10 Microsoft
Market Volatility (90 Days Market Risk)	Dangerous	Very steady	Very steady	Very steady	Very steady	Very steady	Very steady	Very steady	Very steady	Very steady
Market Performance (90 Days Performance)	Insignificant	Solid	Solid	Solid	Solid	Solid	Solid	OK	OK	OK
Odds of Financial Distress (Probability Of Bankruptcy)	About Average	Low	Low	Low	Low	Low	Low	Low	Low	Low
Current Valuation (Equity Enterprise Value)	Over Valued	Under Valued	Under Valued	Under Valued	Under Valued	Under Valued	Under Valued	Over Valued	Over Valued	Over Valued
Buy or Sell Advice (Average Analysts Consensus)	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Trade Advice (90 Days Macroaxis Advice)	Strong Sell	Strong Buy	Strong Buy	Strong Buy	Strong Buy	Strong Buy	Strong Buy	Strong Hold	Strong Hold	Strong Hold
Z Score	N/A	16.6	16.6	16.6	16.6	16.6	16.6	28.8	28.8	28.8
Net Asset	N/A	352.75 B	352.75 B	352.75 B	352.75 B	352.75 B	352.75 B	364.84 B	364.84 B	364.84 B
EBITDA	N/A	133.14 B	133.14 B	133.14 B	133.14 B	133.14 B	133.14 B	100.24 B	100.24 B	100.24 B
Current Valuation	N/A	2.21 T	2.21 T	2.21 T	2.21 T	2.21 T	2.21 T	1.77 T	1.77 T	1.69 T
Price To Book	N/A	45.05	44.76	44.65	44.83	45.38	45.0	10.85	11.59	10.64
Total Asset	N/A	352.75 B	352.75 B	352.75 B	352.75 B	352.75 B	352.75 B	364.84 B	364.84 B	364.84 B
Last Dividend Paid	N/A	0.82	0.82	0.82	0.77	0.82	N/A	0.46	0.46	0.51
Market Capitalization	N/A	2.61 T	2.61 T	2.61 T	2.61 T	2.61 T	2.61 T	2.28 T	2.28 T	2.28 T
Price To Earnings To Growth	N/A	2.78	2.76	2.75	2.76	2.8	2.77	2.23	2.24	2.19
Price To Sales	N/A	5.94	5.9	5.89	5.91	5.98	5.93	9.35	9.37	9.17
Number Of Employees	13	N/A	6	N/A	29	29	N/A	N/A	N/A	N/A
Net Income	N/A	99.8 B	99.8 B	99.8 B	99.8 B	99.8 B	99.8 B	72.74 B	72.74 B	72.74 B
Cash Flow From Operations	N/A	122.15 B	122.15 B	122.15 B	122.15 B	122.15 B	122.15 B	89.03 B	89.03 B	89.03 B
Annual Yield	N/A	0.0098	0.0094	0.0067	0.0099	0.0093	0.0094	0.0095	0.0095	0.0096
Total Debt	N/A	98.96 B	98.96 B	98.96 B	98.96 B	98.96 B	98.96 B	47.03 B	47.03 B	47.03 B
Revenue	N/A	394.33 B	394.33 B	394.33 B	394.33 B	394.33 B	394.33 B	198.27 B	198.27 B	198.27 B
Gross Profit	N/A	N/A	88.19 B	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Day Typical Price	4.14	244.38	244.93	244.92	245.2	244.87	244.92	419.13	420.23	419.48
Accumulation Distribution	N/A	0.32	0.41	0.0031	1.74	0.0653	14.8	0.43	0.12	0.6
Market Facilitation Index	N/A	0.0327	0.0207	0.0033	8.0E-4	0.04	9.0E-4	0.0977	0.0603	0.11
Daily Balance Of Power	(9,223,372,036,855)	1.03125	0.8621	68.0	6.416667	9.375	0.8108	(0.71)	2.028571	(0.46)
Period Momentum Indicator	(0.75)	1.65	1.25	3.4	3.85	7.5	1.5	(3.00)	3.55	(2.40)
Rate Of Daily Change	0.85	1.01	1.01	1.01	1.02	1.03	1.01	0.99	1.01	0.99
Day Median Price	4.14	244.65	245.13	244.93	245.3	244.75	244.88	419.55	420.53	419.68
Price Action Indicator	(0.37)	0.025	0.05	1.68	1.63	4.1	0.88	(2.75)	0.9	(1.77)
Coefficient Of Variation	3657.35	391.32	400.13	394.54	435.08	428.78	381.83	1105.33	1233.52	1197.89
Mean Deviation	6.07	0.8821	0.8458	0.8559	0.9279	0.9516	0.8352	0.9588	1.05	1.0
Jensen Alpha	0.3086	0.2656	0.2566	0.2574	0.2739	0.2812	0.2736	0.1078	0.1075	0.113
Total Risk Alpha	(0.03)	0.2382	0.2311	0.2338	0.2381	0.2458	0.2457	0.0728	0.0662	0.0716
Sortino Ratio	0.0322	0.2115	0.1901	0.2176	0.1764	0.2417	0.2066	0.066	0.0587	0.058
Downside Variance	54.48	1.37	1.59	1.24	2.03	1.15	1.52	1.83	2.15	2.53
Standard Deviation	9.9	1.1	1.09	1.09	1.24	1.25	1.1	1.35	1.47	1.5
Kurtosis	11.1	0.182	0.6365	(0.12)	1.44	0.1739	3.05	5.32	3.36	9.51
Potential Upside	15.31	1.81	1.88	2.06	2.22	2.83	1.88	2.55	2.35	2.42
Treynor Ratio	(0.13)	1.34	0.9353	0.7542	15.95	5.15	1.52	0.5708	1.51	1.06
Maximum Drawdown	69.62	4.97	5.24	4.5	6.45	5.24	6.46	8.71	9.11	11.42
Variance	98.08	1.2	1.19	1.18	1.53	1.57	1.21	1.83	2.16	2.26
Market Risk Adjusted Performance	(0.12)	1.35	0.9453	0.7642	15.96	5.16	1.53	0.5808	1.52	1.07
Risk Adjusted Performance	0.0309	0.2053	0.2008	0.2035	0.1857	0.1885	0.2103	0.0758	0.0688	0.0709
Skewness	2.37	(0.57)	(0.71)	(0.29)	(0.73)	0.2793	(1.09)	(1.10)	(0.55)	(1.63)
Semi Deviation	6.86	0.892	0.98	0.8385	1.04	0.7405	1.0	1.25	1.38	1.48
Information Ratio	0.024	0.2253	0.2196	0.223	0.203	0.2068	0.2317	0.066	0.0585	0.0614
Value At Risk	(11.29)	(1.75)	(1.73)	(1.76)	(1.83)	(1.69)	(1.61)	(1.46)	(1.75)	(1.66)
Expected Short fall	(7.18)	(0.99)	(0.93)	(0.95)	(0.99)	(1.11)	(0.95)	(1.17)	(1.17)	(1.16)
Downside Deviation	7.38	1.17	1.26	1.11	1.42	1.07	1.23	1.35	1.47	1.59
Semi Variance	47.04	0.7956	0.9605	0.703	1.09	0.5483	1.0	1.55	1.89	2.19

INMED PHARMACEUTICALS Competition Performance Charts

Five steps to successful analysis of INMED PHARMACEUTICALS Competition

INMED PHARMACEUTICALS's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by INMED PHARMACEUTICALS INC in relation to its competition. INMED PHARMACEUTICALS's competition analysis typically involves several steps, including:

Identifying the key players in the market: This involves identifying the major competitors of INMED PHARMACEUTICALS in the market, both direct and indirect, as well as new entrants and disruptive technologies.
Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact INMED PHARMACEUTICALS's competitive landscape.
Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to INMED PHARMACEUTICALS INC, and developing a strategy to address them.
Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.

Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your INMED PHARMACEUTICALS position

In addition to having INMED PHARMACEUTICALS in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Theme ETFs Thematic Idea Now

Theme ETFs

ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Theme ETFs theme has 484 constituents at this time.

You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Theme ETFs Theme or any other thematic opportunities.

View All Next

Launch

Other Information on Investing in INMED Stock

INMED PHARMACEUTICALS financial ratios help investors to determine whether INMED Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in INMED with respect to the benefits of owning INMED PHARMACEUTICALS security.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC